Latanoprost in the treatment of glaucoma and ocular hypertension

Drugs of Today

Volumn 35, Issue 6, 1999, Pages 449-459

  Watson, P G ^a,b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; TIMOLOL;

DRUG ABSORPTION; DRUG ACTIVATION; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; REVIEW; SIDE EFFECT;

EID: 0032780263     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.6.544931     Document Type: Review

References (49)

1. Wilson, F.M., Martone, J.F. Epidemiology of chronic open-angle glaucoma In: The Glaucomas. Ritch, R., Shields, M.B., Krupin, T. (Eds.). Mosby: St. Louis 1996, 754.
2. Dark, A.J., Streeten, B.W. Precapsular film on the aging human lens: Precursor of pseudoexfoliation? Br J Ophthalmol 1990, 74: 717-22.
3. Garner, A., Alexander, R.A. Pseudoexfoliative disease: Histochemical evidence of an affinity with zonular fibres. Br J Ophthalmol 1984, 68: 574-80.
4. Schlotzer-Schrehardt, U., Dorfler, S., Naumann, G.O.H. Immunohistochemical localization of basement membrane components in pseudoexfoliation material of the lens capsule. Curr Eye Res 1992, 11: 343-55.
5. Hovding, G., Aasved, H. Prognostic factors in the development of manifest open angle glaucoma: A long-term follow-up study of hypertensive and normotensive eyes. Acta Ophthalmol 1986, 64: 601-8.
6. Quigley, H.A., Tielsch, J.M., Katz, J. et al. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol 1996, 122: 355-63.
7. Vogel, R., Newson, R.B., Shipley, K. et al. Association between intraocular pressure and loss of visual field in chronic simple glaucoma. Br J Ophthalmol 1990, 74: 3-6.
8. Camras, C.B., Bito, L.Z., Eakins, K.E. Reduction of intraocular pressure by prostaglandin applied topically to the rabbit eye. Invest Ophthalmol Vis Sci 1977, 16: 1125-34.
9. 2α analogue. Adv Prostaglandin Thromboxane Leukot Res 1995, 513-8.
10. 2α isopropylester analogues for glaucoma treatment. Jpn J Ophthalmol 1993, 37: 259-69.
11. 2α-1-isopropylester in the cynomologus monkey. Exp Eye Res 1989, 48: 707-16.
12. 2α increases uveoscleral outflow in the cynomologus monkey. Exp Eye Res 1989, 49: 389-402.
13. 2α. Curr Eye Res 1981, 1: 205-9.
14. Bito, L.Z., Camras, C.B., Glenwood, C.G., Resul, R. The ocular hypotensive effects and side effects of prostaglandins on the eye of experimental animals. In: Ocular Effects of Prostaglandins and other Eicosanoids. Bito, L.Z., Stjernschantz, J. (Eds.). Alan R. Liss: New York 1989, 349-68.
15. Mishima, H.K., Kiuchi, Y., Takamatsu, K., Racz, P., Bito, L. Circadian intraocular pressure management with latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 1997, 41 (Suppl. 2): S139-44.
16. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993, 100: 1297-304.
17. Alm, A., Villumsen, J. PhXA34, a new potent ocular hypotensive drug. Arch Ophthalmol 1991, 109: 1564-8.
18. 2α analogue: Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992, 76: 214-7.
19. Camras, C.B., Schumer, R.A., Marsk, A. et al. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol 1992, 110: 1733-8.
20. Alm, A., Villumsen, J., Tornquist, P. et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. Ophthalmology 1993, 100: 1312-7.
21. Hotehama, Y., Mishima, H.K., Kitazawa, Y., Masuda, K. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol 1993, 37: 270-4.
22. Nagasubramanian, S., Sheth, G.P., Hitchins, R.A., Stjernschantz, J. Intraocular pressure reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993, 100: 1305-11.
23. Racz, P., Ruzsonyi, M.R., Gagy, Z.Z.Z., Bito, L.Z. Around the clock intraocular pressure reduction with once daily latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996, 114: 268-73.
24. Stjernschantz, J. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995, 79: 12-6.
25. Lusky, K., Ticho, U., Glovinsky, J. et al. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure. Ophthalmology 1997, 104: 1720-4.
26. Alm, A., Stjernschantz, J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995, 102: 1743-52.
27. Watson, P.G., Stjernschantz, J. A six-month, randomized, double-masked study comparing latanoprost to timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996, 103: 126-37.
28. Camras, C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996, 103: 138-47.
29. Kjellgren, D., Douglas, G., Mikelberg, F.S., Drance, S.K., Alm, A. The short time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand 1995, 73: 233-6.
30. Rulo, A.K., Greve, E.L., Geijssen, H.C., Hoyng, P.F.J. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal pressure glaucoma. Ophthalmology 1996, 103: 1276-82.
31. Hedner, J., Svedmyr, N., Lunde, H., Mandahl, A. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 1997, 41 (Suppl. 2): S111-5.
32. Selen, G., Stjernschantz, J., Resul, B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997, 41 (Suppl. 2): S125-8.
33. Wistrand, R.J., Stjernschantz, J., Olsson, K. The incidence and time course of latanoprost induced iris pigmentation as a function of eye colour. Surv Ophthalmol 1997, 41: 5129-38.
34. Burkhardt, A. The color and structure of the human iris (1). Morphological studies. Anthropol Anz 1992, 50: 83-126.
35. Eagle, R.C. Iris pigmentation and pigmented lesions: An ultrastructural study. Trans Am Ophthalmol Soc 1988, 86: 581-687.
36. Astin, K., Gjotterberg, M., Holst, A., Selen, G., Resul, B., Stjernschantz, J. A study of the fundus in phakic and aphakic monkey eyes treated with PhXA41. Invest Ophthalmol Vis Sci 1992, 33: 1078.
37. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993, 111: 1351-8.
38. 2a-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993, 37: 259-69.
39. Fechtner, R.D., Khouri, A.S., Zimmerman, T.J. et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998, 126: 37-41.
40. Callanan, D., Fellman, R.L., Savage, J.A. Latanoprost associated cystoid macular oedema. Am J Ophthalmol 1998, 126: 134-5.
41. Camras, C.B., Shumar, R.A., Mandahl, A. Occurrence of cystoid macular oedema (CME) in patients treated with latanoprost. Presented at the Am Acad Ophthalmol (Nov) 1998.
42. 2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994, 78: 899-902.
43. Alm, A., Widengard, I., Kjellgren, D. et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995, 79: 12-6.
44. Widegard, I., Maepea, O., Alm, A. Effects of latanoprost and dipiveprin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol 1998, 82: 404-6.
45. Rulo, A.M., Greve, E.L., Hoyng, P.F.J. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology 1997, 104: 1503-7.
46. Susanna, R., Nicolela, M.T., Oga, E. Latanoprost additional reduction in intraocular pressure in patients using dorzolamide and timolol. Rev Bras Oftalmol 1998, 57: 129-34.
47. 2α. Arch Ophthalmol 1987, 105: 1112-6.
48. 2α analogue PhXA41 in eyes treated with pilocarpine and timolol. Cong Eur Glaucoma Soc (Amsterdam) 1992, Abst.
49. Fristrom, B., Nilsson, S.E.G. Interaction of PhXA41 a new prostaglandin analogue with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993, 111: 662-5.